Stephanie Fagan, MS

Chief Corporate Affairs Officer

Stephanie Fagan serves as Chief Corporate Affairs Officer overseeing public affairs and corporate communications to advance the company’s mission to improve outcomes for people living with brain health disorders. She brings over 20 years of experience as an executive in the healthcare industry leading strategies that drive organizational success through innovative communication and stakeholder engagement. Stephanie has deep experience leading corporate affairs and communications in the healthcare industry at Acadia, bluebird bio, Alexion, Shire, Johnson & Johnson, Allergan, Pharmacia (now Pfizer), and Boston Scientific Corporation.

Stephanie is passionate about building and developing the corporate affairs function with high-performing teams that advance business strategies. Her integrated communications expertise spans public affairs, patient advocacy, media relations, investor relations, social and digital media, public relations, branding, and executive and employee communications. Stephanie drives sustainable reputation management strategies that build durable relationships with stakeholders and is a battle-tested counselor steering companies through complex crisis and governance issues.

Outside the office, Stephanie is committed to advancing the communications field and serves as an adjunct professor teaching graduate and undergraduate communication courses at Boston University and Northeastern University. Stephanie received her Master of Science in Mass Communications from Boston University and her Bachelor of Arts in English Literature from Wheaton College.

Carol Vallone

Chair of the Board of Directors, Chair of Compensation Committee, Member of Audit/Finance Committee

Andreas Krebs

Vice Chair of the Board of Directors, Chair of Nomination and Governance Committee, Member of Audit/Finance Committee

David Gryska

Board Director, Chair of Audit Committee

Roger Crystal, MD

Board Director, Member of Nomination & Governance Committee, Member of Compensation Committee

Robert Barrow

Chief Executive Officer and Board Director

Suzanne Bruhn, PhD

Board Director, Member of Nomination & Governance Committee, Member of Compensation Committee

Miri Halperin Wernli, PhD

Executive President

Daniel Karlin, MD, MA

Chief Medical Officer

Mark Sullivan, JD

Chief Legal Officer and Corporate Secretary

Francois Lilienthal, MD, MBA

Chief Commercial Officer

Carrie Liao, CPA

Chief Accounting Officer

Stephanie Fagan, MS

Chief Corporate Affairs Officer

Robert Malenka, MD, PhD

Chairman of the Scientific Advisory Board, Nancy Friend Pritzker Professor in Psychiatry and Behavioral Sciences at Stanford University

Peter Bergethon, MD

Member, Scientific Advisory Board VP, Head of Quantitative & Clinical Technologies, Biogen, Inc.

Robert Dworkin, PhD

Professor of Anesthesiology and Perioperative Medicine, Neurology, and Psychiatry at University of Rochester

Maurizio Fava, MD

Psychiatrist-in-Chief of the Massachusetts General Hospital (MGH)

Carole Abel, MBA

VP, Programs and Portfolio Office (PPO)

Peter Mack, PhD

VP, Pharmaceutical Development

Michael Seggev

VP, Global Marketing, Strategic Insights and Digital Innovation

Rafael Muniz, MD

VP, Global Medical Affairs

Phong Duong, PharmD

VP, Global Market Access and Health Economics

Maria Oquendo, MD, PhD

Ruth Meltzer Professor and Chairman of Psychiatry at University of Pennsylvania, Psychiatrist-in-Chief at the Hospital of the University of Pennsylvania

Matthias Liechti, MD, PhD

Scientific Collaborator & Advisor

Kim PC Kuypers, PhD

Scientific Collaborator & Advisor

Peter Gasser, MD

Clinical Advisor